<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990912</url>
  </required_header>
  <id_info>
    <org_study_id>CA124-003</org_study_id>
    <nct_id>NCT00990912</nct_id>
  </id_info>
  <brief_title>A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)</brief_title>
  <official_title>A Study to Document Long-term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects 1 - 21 Years of Age With Refractory Solid Tumors Who Have Experienced Clinical Benefit Following a Minimum of 6 Cycles of Therapy on BMS Protocol CA124-001 or BMS Protocol CA124-002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long term safety of patients with refractory
      solid tumors who have experienced clinical benefit after at least 6 cycles of treatment in
      BMS Protocol CA124-001 or CA124-002.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety and tolerability</measure>
    <time_frame>22 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of duration of clinical benefit per CT or MRI, steroid use and neuropathy assessment</measure>
    <time_frame>Every other cycle for 22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pediatric Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan (12 (9) mg/m²/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan (10 (10) mg/m²/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity</description>
    <arm_group_label>Carboplatin</arm_group_label>
    <other_name>Paraplatin</other_name>
    <other_name>BMY-26575</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity</description>
    <arm_group_label>Irinotecan (12 (9) mg/m²/day)</arm_group_label>
    <other_name>Camptosar</other_name>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity</description>
    <arm_group_label>Irinotecan (10 (10) mg/m²/day</arm_group_label>
    <other_name>Camptosar</other_name>
    <other_name>Campto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of at least 6 cycles of therapy on BMS clinical protocol CA124-001 or
             CA124-002 and who continue to derive clinical benefit and are not experiencing
             intolerable toxicity from the therapy

          -  Karnofsky score of at least 50 for subjects &gt; 10 years of age; Lansky play scale of at
             least 50 for children 10 years of age and younger

          -  Recovery to baseline or Grade 1 from toxicities (except alopecia or asthenia)
             resulting from previous therapies

          -  Males and females, ages 1 - 21 years of age at the time of consent into CA124-001 or
             CA124-002

        Exclusion Criteria:

          -  A serious uncontrolled medical disorder that in the opinion of the Investigator would
             impair the ability of the subject to receive protocol therapy

          -  Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy, or any
             other investigational drug while on study

          -  Inadequate bone marrow and renal function

          -  Concurrent receipt of Dilantin®(phenytoin), phenobarbital, primidone,
             Tegretol®(carbamazepine), Depacon®, Depakene®, Depakote®, and Deproic®(valproic acid)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <disposition_first_submitted>February 3, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 3, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 5, 2010</disposition_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

